Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07

BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC) is rare with a poor outcome and is resistant to conventional cytotoxic chemotherapy. The efficacy and safety of durvalumab and tremelimumab for treating recurrent or metastatic PSCs were assessed by a nonrandomized, open‐label, phase II study. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Miso, Keam, Bhumsuk, Ock, Chan‐Young, Kim, Se Hyun, Kim, Yu Jung, Lim, Sun Min, Kim, Jin‐Soo, Kim, Tae Min, Hong, Sook‐Hee, Ahn, Mi Sun, Shin, Seong Hoon, Kang, Eun Joo, Kim, Dong‐Wan, Im, Sun‐Wha, Kim, Jong‐Il, Lee, Jong Seok, Kim, Joo‐Hang, Heo, Dae Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705626/
https://www.ncbi.nlm.nih.gov/pubmed/33026712
http://dx.doi.org/10.1111/1759-7714.13684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705626/
https://www.ncbi.nlm.nih.gov/pubmed/33026712
http://dx.doi.org/10.1111/1759-7714.13684

Ejemplares similares